"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at intetumumab, with or without dacarbazine (DTIC), for advanced melanoma
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at intetumumab (also called CNTO 95), with or without dacarbazine (DTIC), for advanced melanoma skin cancer.
Doctors sometimes use dacarbazine to treat melanoma that has spread. It helps to control the growth of melanoma in some people. But unfortunately this is usually temporary and the cancer starts to grow again.
Intetumumab is a type of biological therapy called a monoclonal antibody. Intetumumab blocks the action of proteins called integrins. These are found on the surface of cells. Some cancers use these integrins to form new blood vessels so that they can get the food and oxygen they need to continue growing. Doctors hoped that if they can stop cancers from forming new blood vessels, this would slow or stop the growth of the cancer.
The aims of this trial were to find out
- How well intetumumab works as a treatment for advanced melanoma
- More about the side effects
Summary of results
The research team found that there was a possible small benefit with using intetumumab for advanced melanoma, but that more research needs to be done.
This trial recruited 129 people from the UK, America and Germany into 1 of 4 groups. The different groups had different doses of the trial drug.
- Group 1 had dacarbazine and a dummy drug (placebo)
- Group 2 had dacarbazine and intetumumab at a higher dose
- Group 3 had intetumumab alone at a higher dose
- Group 4 had intetumumab alone at a lower dose
The research team looked at how long it took for the melanoma to start growing again. The results showed that there was a small difference between the people who had dacarbazine and intetumumab (group 2) and the other groups. But the difference was not enough to be significant in statistical terms.
They also looked at how long people lived for. There was a small increase for the people who had the higher dose of intetumumab (groups 2 and 3) compared to the other groups. But again, it wasn't a big enough difference to be significant in statistical terms.
The most common side effects included headache, tiredness, sickness and pain at the injection site. These were mostly mild and affected people in all 4 groups. About 1 out of every 4 people who had intetumumab had temporary inflammation of the eye with the first cycle of treatment.
The research team concluded that although the results could have happened by chance (they weren't
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor M. Gore
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer